Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-TM601 in Progressive/Recurrent Malignant Glioma
NCT00683761Phase 2Unknown
- Sponsor
- TransMolecular
- Start
- Aug 2008
- Primary completion
- Feb 2010
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 131i-tm601 in malignant glioma, sponsored by TransMolecular. Primary endpoints: Safety and tolerability of multiple doses of intravenously administered 131I-TM601, Clinical response to 131I-TM601 and 3 more. Status: unknown.
02
Drugs
131i-tm601
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00683761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683761.